At the same time the RALES and EPHESUS trials showed that aldosterone antagonism on top of Ang II blockade provided a major additive benefit as it reduced significantly overall mortality and the rate of death from cardiovascular causes among patients with severe heart failure [84] or after acute myocardial infarction [85]. This evidence concerns the gene AGT and myocardial infarction.